Lower hemoglobin levels in patients with parkinson's disease are associated with disease severity and iron metabolism

Qingyuan, Deng; Zhou, Xiao; Chen, Jinyu; Pan, Mengqiu; Gao, Hong; Zhou, Jing; Wang, Dongmei; Chen, Qiong; Zhang, Xiaomei; Wang, Qun; Xu, Yunqi

doi:10.1016/j.brainres.2016.11.007

Cited by 38 publications

(30 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strikingly, individuals who developed PD had anemia or low hemoglobin levels as early as 20 years before the onset of motor symptoms (Savica et al, 2009) suggesting that the presence of anemia or low hemoglobin levels may be one of the earliest predictors of PD. Furthermore, low levels of hemoglobin have been associated with disease severity in PD patients and late stage PD patients had lower levels of iron, ferritin, and total iron binding capacity compared to age-matched HCs (Deng et al, 2016). A recent study in a Taiwanese cohort of 86,334 patients demonstrated that newly diagnosed anemic patients have a higher risk of developing PD four or more years after the initial diagnosis of anemia (Hong et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson’ Disease

Santiago

Potashkin

2017

Front. Aging Neurosci.

View full text Add to dashboard Cite

Disrupted iron metabolism has been implicated in the pathogenesis of Parkinson’s disease (PD), a progressive neurodegenerative disorder that severely affects movement and coordination, yet the molecular mechanisms underlying this association remain unknown. To this end, we performed a transcriptomic meta-analysis of four blood microarrays in PD. We observed a significant downregulation of genes related to hemoglobin including, hemoglobin delta (HBD), alpha hemoglobin stabilizing protein (ASHP), genes implicated in iron metabolism including, solute carrier family 11 member 2 (SLC11A2), ferrochelatase (FECH), and erythrocyte-specific genes including erythrocyte membrane protein (EPB42), and 5′-aminolevulinate synthase 2 (ALAS2). Pathway and network analysis identified enrichment in processes related to mitochondrial membrane, oxygen transport, oxygen and heme binding, hemoglobin complex, erythrocyte development, tetrapyrrole metabolism and the spliceosome. Collectively, we identified a subnetwork of genes in blood that may provide a molecular explanation for the disrupted hemoglobin and iron metabolism in the pathogenesis of PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson’ Disease

Santiago

Potashkin

2017

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…ID anemia and low Hb have also been associated with PD i.e., with increased risk and disease severity [245]. Furthermore, it has been documented that PD patients exhibit lower ferritin, TIBC, and serum iron levels [245]. A positive correlation between anemia and PD was found in a recent large study of 86,334 newly diagnosed anemic patients.…”

Section: Iron and Parkinson's Diseasementioning

confidence: 99%

Age-Related Changes and Sex-Related Differences in Brain Iron Metabolism

Kezele

Ćurko-Cofek

2020

Nutrients

View full text Add to dashboard Cite

Iron is an essential element that participates in numerous cellular processes. Any disruption of iron homeostasis leads to either iron deficiency or iron overload, which can be detrimental for humans’ health, especially in elderly. Each of these changes contributes to the faster development of many neurological disorders or stimulates progression of already present diseases. Age-related cellular and molecular alterations in iron metabolism can also lead to iron dyshomeostasis and deposition. Iron deposits can contribute to the development of inflammation, abnormal protein aggregation, and degeneration in the central nervous system (CNS), leading to the progressive decline in cognitive processes, contributing to pathophysiology of stroke and dysfunctions of body metabolism. Besides, since iron plays an important role in both neuroprotection and neurodegeneration, dietary iron homeostasis should be considered with caution. Recently, there has been increased interest in sex-related differences in iron metabolism and iron homeostasis. These differences have not yet been fully elucidated. In this review we will discuss the latest discoveries in iron metabolism, age-related changes, along with the sex differences in iron content in serum and brain, within the healthy aging population and in neurological disorders such as multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and stroke.

show abstract

“…These findings are supported by recent studies in different populations. For instance, lower levels of hemoglobin associated with disease severity in PD patients (Deng et al, 2017 ). Recently, a positive association between anemia and PD was found in a large study of 86,334 newly diagnosed anemic patients.…”

Section: Anemia and Parkinson’s Diseasementioning

confidence: 99%

“…It has been documented that PD patients exhibit lower serum iron levels (Savica et al, 2009 ; Pichler et al, 2013 ; Medeiros et al, 2016 ). Interestingly, late stage PD patients had lower levels of iron, ferritin and total iron binding capacity suggesting that markers of disrupted iron metabolism could be useful markers for disease stratification in PD (Deng et al, 2017 ). A recent transcriptomic meta-analysis identified a significant downregulation of genes associated with hemoglobin and iron metabolism including, hemoglobin delta ( HBD ), alpha hemoglobin stabilizing protein ( ASHP ) and solute carrier family 11 member 2 ( SLC11A2 ) in blood of PD, thus reinforcing the relevance of these pathways in the disease pathogenesis (Santiago and Potashkin, 2017 ).…”

Section: Anemia and Parkinson’s Diseasementioning

confidence: 99%

Biological and Clinical Implications of Comorbidities in Parkinson’s Disease

Santiago

Bottero

Potashkin

2017

Front. Aging Neurosci.

View full text Add to dashboard Cite

A wide spectrum of comorbidities has been associated with Parkinson’s disease (PD), a progressive neurodegenerative disease that affects more than seven million people worldwide. Emerging evidence indicates that chronic diseases including diabetes, depression, anemia and cancer may be implicated in the pathogenesis and progression of PD. Recent epidemiological studies suggest that some of these comorbidities may increase the risk of PD and precede the onset of motor symptoms. Further, drugs to treat diabetes and cancer have elicited neuroprotective effects in PD models. Nonetheless, the mechanisms underlying the occurrence of these comorbidities remain elusive. Herein, we discuss the biological and clinical implications of comorbidities in the pathogenesis, progression, and clinical management, with an emphasis on personalized medicine applications for PD.

show abstract

Lower hemoglobin levels in patients with parkinson's disease are associated with disease severity and iron metabolism

Cited by 38 publications

References 37 publications

Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson’ Disease

Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson’ Disease

Age-Related Changes and Sex-Related Differences in Brain Iron Metabolism

Biological and Clinical Implications of Comorbidities in Parkinson’s Disease

Contact Info

Product

Resources

About